Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
44 results
D1.216 - From Acetaminophen to sauerkraut
D1.217 - Rapid drug desensitization in children: case report
D1.219 - Impact of a Penicillin Allergy Delabeling Program on Antibiotic Selection and Perioperative Outcomes: A Prospective Comparative Cohort Study
D1.222 - Comparative analysis and evaluation of clinical and stewardship implications of parent reported antibiotic allergy labels within paediatric care
D1.223 - Evaluation of Immediate-Type Allergic Reactions to Amide Group Local Anesthetics In Children: A Single-Center
D1.224 - Clinical performance of IgE Quaternary Ammoniums, Atracurium, Rocuronium and Suxamethonium for the diagnosis of an allergy to curares
D1.225 - Direct single dose mass delabelling of antibiotic allergy in paediatrics
D1.226 - Increased incidence of suspected clindamycin hypersensitivity reactions in pediatric patients due to its expanded use in clinical practice
D1.227 - Risk stratification of drug allergy in children with immediate or delayed urticaria during antibiotic treatment
D1.228 - Patch testing and HLA genotyping as diagnostic tools for DRESS related to concomitant multidrug exposure
D1.229 - Limited interest of suxamethonium, rocuronium and atracurium specific IgE reagents for the diagnosis of NMBA allergy sensitization
D1.230 - Acute Localized Exanthemathous pustulosis induced by Pertuzumab and Trastuzumab with positive Lymphocyte Transformation test
D1.231 - When Antihistamines Paradoxically Worsen Chronic Spontaneous Urticaria: Trust Your Patient
D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117
D2.354 - Questionnaire survey of new treatments for atopic dermatitis
D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience
Pagination
Current page
1
Page
2
Page
3
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download